Regeneron price target raised to $1,040 from $1,025 at BMO Capital

BMO Capital analyst Evan Seigerman raised the firm’s price target on Regeneron to $1,040 from $1,025 and keeps an Outperform rating on the shares. The analyst is updating BMO’s model to reflect the firm’s confidence in Dupixent’s commercial COPD opportunity, assigning 90% probability of success for the drug following validation BOREAS Phase 3 study readout and no competition in severe COPD. Regeneron’s ability to translate R&D spend to enterprise value growth should not be underestimated, the firm tells investors in a research note.